Antiplatelet combination therapy

This page covers all Antiplatelet combination therapy drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Cyclooxygenase (COX) and P2Y12 receptor, COX-1 (aspirin); PDE-3 (cilostazol).

Targets

Cyclooxygenase (COX) and P2Y12 receptor · COX-1 (aspirin); PDE-3 (cilostazol)

Marketed (3)

• Conventional DAPT · Zunyi Medical College · Cardiovascular
  Conventional DAPT (Dual Antiplatelet Therapy) combines two antiplatelet agents to inhibit platelet aggregation through different pathways, reducing thrombotic events.
• DAPT on-target · Kaiser Franz Josef Hospital · Cardiovascular
  DAPT (dual antiplatelet therapy) on-target inhibits platelet aggregation through simultaneous blockade of multiple platelet activation pathways to prevent thrombotic events.
• Double antiplatelet therapy · University Hospital, Bordeaux · Cardiovascular
  Double antiplatelet therapy combines two antiplatelet agents to inhibit platelet aggregation through different mechanisms, reducing thrombotic events.

Phase 3 pipeline (1)

• Asprin, Cilostazol · Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan · Cardiovascular
  This combination of aspirin (antiplatelet) and cilostazol (phosphodiesterase-3 inhibitor) works synergistically to inhibit platelet aggregation and improve blood flow.